173 related articles for article (PubMed ID: 38030058)
1. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
[TBL] [Abstract][Full Text] [Related]
2. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
Krejner-Bienias A; Grzela K; Grzela T
Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):1. PubMed ID: 33527308
[TBL] [Abstract][Full Text] [Related]
3. Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM).
Carpio LE; Olivares M; Benítez-Paez A; Serrano-Candelas E; Barigye SJ; Sanz Y; Gozalbes R
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891933
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
6. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins.
Alade AA; Ahmed SA; Mujwar S; Kikiowo B; Akinnusi PA; Olubode SO; Olufemi OM; Ohilebo AA
J Biomol Struct Dyn; 2024 May; 42(8):4029-4047. PubMed ID: 37261796
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
Solerte SB; Di Sabatino A; Galli M; Fiorina P
Acta Diabetol; 2020 Jul; 57(7):779-783. PubMed ID: 32506195
[TBL] [Abstract][Full Text] [Related]
8. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
Remm F; Franz WM; Brenner C
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
[TBL] [Abstract][Full Text] [Related]
9. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
Front Immunol; 2022; 13():942131. PubMed ID: 35958564
[TBL] [Abstract][Full Text] [Related]
10. Gliptins in managing diabetes - Reviewing computational strategy.
Sneha P; Doss CG
Life Sci; 2016 Dec; 166():108-120. PubMed ID: 27744054
[TBL] [Abstract][Full Text] [Related]
11. Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network.
Gao Q; Zhang W; Li T; Yang G; Zhu W; Chen N; Jin H
Sci Rep; 2022 Jan; 12(1):188. PubMed ID: 34996987
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
[TBL] [Abstract][Full Text] [Related]
13. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.
Ogundipe O; Mazidi M; Chin KL; Gor D; McGovern A; Sahle BW; Jermendy G; Korhonen MJ; Appiah B; Ademi Z; De Bruin ML; Liew D; Ofori-Asenso R
Acta Diabetol; 2021 Jan; 58(1):39-46. PubMed ID: 32809070
[TBL] [Abstract][Full Text] [Related]
14. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
15. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
[TBL] [Abstract][Full Text] [Related]
16. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths.
Strollo R; Maddaloni E; Dauriz M; Pedone C; Buzzetti R; Pozzilli P
Diabetes Res Clin Pract; 2021 Jan; 171():108444. PubMed ID: 32946854
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
18. Investigation of CD26, a potential SARS-CoV-2 receptor, as a biomarker of age and pathology.
Raha AA; Chakraborty S; Henderson J; Mukaetova-Ladinska E; Zaman S; Trowsdale J; Raha-Chowdhury R
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33205807
[TBL] [Abstract][Full Text] [Related]
19. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
Birnbaum Y; Bajaj M; Yang HC; Ye Y
Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
[TBL] [Abstract][Full Text] [Related]
20. Plasma metabolome and cytokine profile reveal glycylproline modulating antibody fading in convalescent COVID-19 patients.
Yang Z; Wu D; Lu S; Qiu Y; Hua Z; Tan F; Zhang C; Zhang L; Zhang DY; Zhou X; Cai Z; Shang Y; Lin SH
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2117089119. PubMed ID: 35943976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
